Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (227)	9/4/2002 12:21:56 PM
From: keokalani'nui	Read Replies (1) of 824

Thanks, Biomaven. Not much new there, but a 8,000+ patient study from this center ought to carry some weight. I'm a little worried about the excess ckmb/death correlation not showing up until 3-4 months (if that is true, can't really tell from the abstract), I think pexeli's EPs are measured at 30 days, and it's unlikely they would ever extend the dose more than 12/24 hours post op. Intelligent posters on Y! thread have hoped for consistent use of ace-inhibitors and statins in P3; no one knows if P3 includes this in protocol or controls for it. Nice overall conclusion, however. Several of these factors suggest that inflammation may play a part in the excess risk of death. Topol et al would be very influential if pexeli does any good in MI. Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next